Gravity Analytica

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

BCYC 01.09.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-14

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our BCYC Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, England&BOSTON--(BUSINESS WIRE)--Jan. 9, 2025--Bicycle Therapeutics plc(NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that management will participate at the 43^rdAnnualJ.P. Morgan Healthcare Conferencein a podium presentation onTuesday, Jan. 14, at5:15 p.m. PT, followed by a question-and-answer breakout session at5:35 p.m. PT.

A live webcast of the presentation will be accessible from the Investor section of the company’s website atwww.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

AboutBicycle TherapeuticsBicycle Therapeuticsis a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle^®molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle^®Toxin Conjugate (BTC^®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist^®(Bicycle TICA^®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC^®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle^®technology to develop therapies for diseases beyond oncology.

Bicycle Therapeuticsis headquartered inCambridge, UK, with many key functions and members of its leadership team located inCambridge, Mass.For more information, visitwww.bicycletherapeutics.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250109465188/en/

Investors:Stephanie YaoSVP, Investor Relations and Corporate Communicationsstephanie.yao@bicycletx.com857-523-8544

Matthew DeYoungArgot Partnersir@bicycletx.com212-600-1902

Media:Jim O’ConnellWeber Shandwickmedia@bicycletx.com312-988-2343

Source:Bicycle Therapeutics plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com